Target intelligence / Profile preview

Hemagglutinin antigen of Influenza B virus (HA)

Target
HA
Molecular classification
Viral fusion protein, Glycoprotein, Receptor-binding protein, Major antigen, Class I viral fusion protein
01

Overview

The **Hemagglutinin antigen of Influenza B virus** is a trimeric viral surface glycoprotein that mediates the virus’s entry into host cells. HA binds to sialic acid-containing receptors on the host cell surface, determining viral attachment and host specificity[1][2][4][5][6]. After receptor binding, HA undergoes a pH-triggered conformational change that drives the fusion of the viral envelope with the endosomal membrane, allowing genomic entry[1][2][5][6]. It is the major antigenic determinant of the Influenza B virus, being the principal target of neutralizing antibodies and the primary component evaluated in seasonal influenza vaccines[5][6]. HA structural variability underlies both susceptibility to immune recognition (hence the efficacy of vaccines and antibodies) and the antigenic drift that necessitates frequent vaccine updates[3][5][6]. Because of its essential role in infection and immunogenicity, HA is a leading therapeutic and diagnostic target in influenza research and public health[4][5][6]. **Notes:** - No small-molecule drugs directly target HA in Influenza B infection; anti-HA monoclonal antibodies are an area of research, and vaccines are the main interacting interventions. - "Hemagglutinin" can refer to analogous proteins in other viruses (such as Influenza A), but structure, sequence, and immunogenicity may differ substantially between types[2][3]. - For structural and epitope details, the HA from Influenza B shows about 25% sequence identity with that of Influenza A, though domain organization is conserved[3][2]. - The standard functional assays for anti-HA immunity include the hemagglutination inhibition assay[5]. If more specificity is needed (e.g., strain/subtype context), include the appropriate strain name or subtype.

Other names
Hemagglutinin (Influenza B)Influenza B hemagglutininHA (Influenza B)B/Lee/1940 HAHAb
02

Mechanism of action

Neutralizing antibodies bind HA, blocking receptor binding or fusion; Vaccines induce antibodies targeting HA to prevent infection

03

Biological functions

Viral attachment to host cellMediates membrane fusionImmune response activation (main antigenic target for neutralizing antibodies)Host specificity determination
04

Disease associations

Infection (Influenza)
05

Safety considerations

Antigenic drift and shift cause immune escape, limiting vaccine effectivenessDifficulty in targeting due to variability of antigenic sites
06

Interacting drugs

None approved directly targeting HA for Influenza B; vaccines elicit anti-HA antibodies

1 more in the full profile.

07

Biomarkers

Presence or level of anti-hemagglutinin antibodies (post-vaccination or infection)Hemagglutination inhibition (HI) antibody titer

Beyond the preview

Go deeper on Hemagglutinin antigen of Influenza B virus (HA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemagglutinin antigen of Influenza B virus (HA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call